BMO Capital Markets began coverage on shares of Repare Therapeutics (NASDAQ:PAND) in a research note published on Monday, BenzingaRatingsTable reports. The firm issued an outperform rating and a $29.00 price objective on the stock.

NASDAQ:PAND opened at $18.85 on Monday. Repare Therapeutics has a fifty-two week low of $16.67 and a fifty-two week high of $27.75.

In other news, Director Plc Glaxosmithkline bought 361,111 shares of the business’s stock in a transaction on Tuesday, July 21st. The shares were purchased at an average price of $18.00 per share, for a total transaction of $6,499,998.00.

Repare Therapeutics Company Profile

Pandion Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on developing various therapeutics to address the unmet needs of patients suffering from autoimmune diseases. Its lead product candidate is PT101, an effector module comprised of an engineered variant of wild-type interleukin-2 (IL-2) fused to a protein backbone that is in Phase 1a clinical trials for the treatment of various autoimmune and inflammatory diseases.

See Also: The components of the Stochastic Momentum Index

Receive News & Ratings for Repare Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repare Therapeutics and related companies with's FREE daily email newsletter.